SPOTLIGHT -
July 2nd 2024
Kisunla (donanemab-azbt) is now approved by the FDA for adults with early symptomatic Alzheimer disease.
June 17th 2024
Review the multiple uses of metformin.
June 15th 2024
Here are highlights from the week in Psychiatric Times.
June 10th 2024
The FDA Advisory Committee recommended donanemab, which could lead to its approval later this year.
May 18th 2024